FOOD AND FASTING PERIODS AS MEDICINE TO PREVENT DISEASE
Professor Leonie Heilbronn
University of Adelaide &
Group Leader Obesity and Metabolism,
South Australian Health and Medical Research Institute (SAHMRI)
Adelaide, South Australia
RESEARCHER PROFILE
Filmed in Adelaide, South Australia | February 2025
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
Prof. Heilbronn is a translational investigator in obesity and diabetes research. She has a particular interest in understanding how fasting and meal timing alter nutrient signalling pathways to improve health and contributed extensively to current concepts in calorie restriction, intermittent fasting and time restricted eating. She has published more than 140 peer-reviewed manuscripts, and has a current h-index of 44. She is an Associate Editor of Obesity and the European Journal of Endocrinology. She is President of the Australia and New Zealand Obesity Society and an Associate Member of the Australian Academy of Health and Medical Science.
-
Hormone receptor positive breast cancer and therapy resistance
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
-
Dr Lisa Melton
RESEARCH IN SANFILIPPO
@ SANFILIPPO CHILDREN’S FOUNDATION
SYDNEY, NEW SOUTH WALES, AUSTRALIA -
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
